Clinically tested by endocrinologists, - can deliver noticeable results in just 7 days, dramatically improving obesity and a range of associated health issues
Eli Lillys new GLP-1 candidate orforglipron is expected to be filed for regulatory approval towards the end of 2025, with the earliest date of approval anticipated to be mid-2026
The implication for independent operators: the right response depends on your concept's occasion type, not a generic adjustment to the trend
Our injection device guide covers all available options
For type 2 diabetes, NICE recommends continuing GLP-1 therapy only if HbA1c falls by 11 mmol/mol AND body weight reduces by 3% at 6 months
Several clinical scenarios warrant discussion: You should consider speaking with your GP if: You have type 2 diabetes that is inadequately controlled despite lifestyle modifications and metformin therapy, and your HbA1c remains above target You are struggling with weight management despite optimised thyroid hormone replacement, and you might meet NICE criteria for medical weight management (typically requiring referral to specialist weight management services) You have cardiovascular disease alongside type 2 diabetes, as some GLP-1 agonists (semaglutide, liraglutide, dulaglutide) have demonstrated cardiovascular benefits Your current diabetes medications are causing problematic side effects or hypoglycaemia Before your appointment , it is helpful to: Ensure your thyroid function has been checked recently (within the past 6 months) Compile a list of all current medications, including levothyroxine dose and timing Document your weight history and any previous weight management attempts Note any family history of thyroid cancer or endocrine conditions Prepare questions about potential benefits, risks, and alternatives Your GP will assess your suitability for GLP-1 therapy by reviewing your medical history, current thyroid status, diabetes control (if applicable), and overall health
